patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_797360 | REC_0000101 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 15.6 | 69 | female | 0 | 13 | 6.2 | 2 | alectinib 600 mg BID | 10.9 | false | MSI-H | 2026-03-15T05:35:56.855027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741786 | REC_0000102 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 8.1 | 72 | female | 2 | 16 | 5 | 7 | entrectinib 600 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:56.855279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218660 | REC_0000103 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11.7 | 72 | female | 1 | 12 | 4.8 | 1 | sotorasib 960 mg daily | 6.1 | true | MSS | 2026-03-15T05:35:56.855523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514932 | REC_0000104 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 28 | 4.9 | 61 | female | 1 | 47 | 4.2 | 0 | pembrolizumab 200 mg q3w | 55.3 | true | MSS | 2026-03-15T05:35:56.855757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952815 | REC_0000105 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 4.5 | 63 | male | 0 | 25 | 5.7 | 1 | pembrolizumab 200 mg q3w | 24.9 | false | MSS | 2026-03-15T05:35:56.856159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163962 | REC_0000106 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 13.5 | 58 | male | 1 | 1 | 5 | 2 | osimertinib 80 mg daily | 29.8 | true | MSI-H | 2026-03-15T05:35:56.856452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269769 | REC_0000107 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 6 | 69 | female | 0 | 21 | 6.1 | 0 | sotorasib 960 mg daily | 43.1 | false | MSS | 2026-03-15T05:35:56.856716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427640 | REC_0000108 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 13.1 | 67 | male | 0 | 17 | 7.8 | 1 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:35:56.856964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960105 | REC_0000109 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.5 | 65 | male | 0 | 4 | 6.5 | 6 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:56.857201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578037 | REC_0000110 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.8 | 67 | female | 0 | 10 | 5.7 | 4 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:56.857437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732152 | REC_0000111 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 4.8 | 46 | female | 0 | 42 | 5.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 21.1 | false | MSS | 2026-03-15T05:35:56.857680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246493 | REC_0000112 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 13.3 | 65 | female | 1 | 18 | 6.4 | 2 | pembrolizumab 200 mg q3w | 13 | false | MSI-H | 2026-03-15T05:35:56.857921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330368 | REC_0000113 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.8 | 57 | female | 0 | 37 | 6.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.4 | true | MSS | 2026-03-15T05:35:56.858156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687973 | REC_0000114 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 10 | 71 | male | 2 | 28 | 4.6 | 2 | osimertinib 80 mg daily | 7.4 | true | MSI-H | 2026-03-15T05:35:56.858393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182589 | REC_0000115 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 11.4 | 68 | female | 1 | 18 | 6.1 | 2 | entrectinib 600 mg daily | 19.3 | false | MSI-H | 2026-03-15T05:35:56.858632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852302 | REC_0000116 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 10.1 | 52 | male | 0 | 12 | 5.9 | 2 | entrectinib 600 mg daily | 20.1 | true | MSS | 2026-03-15T05:35:56.858884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711026 | REC_0000117 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 9.6 | 65 | male | 0 | 15 | 4.7 | 1 | pembrolizumab 200 mg q3w | 15.8 | false | MSS | 2026-03-15T05:35:56.859138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537571 | REC_0000118 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.6 | 69 | female | 1 | 10 | 6.8 | 8 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:56.859508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732553 | REC_0000119 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.8 | 63 | female | 1 | 15 | 5.3 | 5 | sotorasib 960 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:56.859775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485977 | REC_0000120 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 12.2 | 51 | female | 0 | 14 | 5.8 | 4 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:56.860014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640510 | REC_0000121 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 16.2 | 57 | female | 1 | 22 | 4.4 | 4 | alectinib 600 mg BID | 13.7 | true | MSI-H | 2026-03-15T05:35:56.860324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191945 | REC_0000122 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 16.8 | 52 | female | 0 | 23 | 5.6 | 1 | osimertinib 80 mg daily | 18.2 | false | MSS | 2026-03-15T05:35:56.860565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841627 | REC_0000123 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9 | 75 | female | 0 | 22 | 4.3 | 2 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:56.860800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577238 | REC_0000124 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5 | 76 | male | 0 | 22 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:35:56.861033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614847 | REC_0000125 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.4 | 61 | male | 0 | 19 | 7.3 | 6 | sotorasib 960 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:56.861270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378935 | REC_0000126 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 13.8 | 69 | female | 0 | 20 | 5.3 | 5 | alectinib 600 mg BID | 16.1 | true | MSS | 2026-03-15T05:35:56.861506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933655 | REC_0000127 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 10.8 | 75 | male | 1 | 25 | 5.9 | 6 | alectinib 600 mg BID | 9.7 | false | MSI-H | 2026-03-15T05:35:56.861744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977270 | REC_0000128 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.4 | 44 | male | 0 | 15 | 6.8 | 10 | alectinib 600 mg BID | 6.4 | false | MSI-H | 2026-03-15T05:35:56.861977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662537 | REC_0000129 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 16.6 | 58 | male | 0 | 9 | 4.9 | 6 | osimertinib 80 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:56.862214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592105 | REC_0000130 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 8.7 | 75 | female | 2 | 24 | 3.8 | 6 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:35:56.862441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137941 | REC_0000131 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 7.9 | 72 | female | 2 | 56 | 2.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.8 | true | MSS | 2026-03-15T05:35:56.862741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458075 | REC_0000132 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 12.4 | 59 | female | 0 | 8 | 7.4 | 7 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:56.862980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167873 | REC_0000133 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 35 | 11.5 | 58 | female | 0 | 14 | 5.6 | 4 | entrectinib 600 mg daily | 4.6 | true | MSI-H | 2026-03-15T05:35:56.863218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601656 | REC_0000134 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 13 | 16.2 | 73 | female | 2 | 12 | 7.5 | 2 | osimertinib 80 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:35:56.863477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341646 | REC_0000135 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.6 | 60 | male | 1 | 13 | 5.2 | 1 | alectinib 600 mg BID | 25.7 | true | MSS | 2026-03-15T05:35:56.863718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429254 | REC_0000136 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 10.1 | 81 | female | 2 | 20 | 5 | 4 | sotorasib 960 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:35:56.863954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444686 | REC_0000137 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.3 | 84 | female | 2 | 8 | 5.5 | 7 | osimertinib 80 mg daily | 10.4 | false | MSS | 2026-03-15T05:35:56.864212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213856 | REC_0000138 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 9.2 | 64 | male | 0 | 55 | 7.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 18 | false | MSS | 2026-03-15T05:35:56.864454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119828 | REC_0000139 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 8.5 | 73 | male | 1 | 21 | 7.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:35:56.864734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391909 | REC_0000140 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.8 | 66 | female | 1 | 17 | 4.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:35:56.865001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372018 | REC_0000141 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 9.4 | 64 | male | 0 | 18 | 5.3 | 2 | alectinib 600 mg BID | 17.8 | true | MSS | 2026-03-15T05:35:56.865288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578656 | REC_0000142 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.6 | 70 | male | 1 | 14 | 5.1 | 7 | sotorasib 960 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:56.865557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361601 | REC_0000143 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.8 | 69 | female | 0 | 19 | 6.1 | 5 | sotorasib 960 mg daily | 14 | false | MSS | 2026-03-15T05:35:56.865812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934190 | REC_0000144 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.6 | 84 | female | 1 | 44 | 6.2 | 6 | pembrolizumab 200 mg q3w | 17.9 | true | MSS | 2026-03-15T05:35:56.866159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948554 | REC_0000145 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 6.8 | 66 | female | 1 | 4 | 5 | 5 | entrectinib 600 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:56.866405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837970 | REC_0000146 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 11.5 | 75 | female | 2 | 13 | 6.9 | 2 | entrectinib 600 mg daily | 18.4 | true | MSI-H | 2026-03-15T05:35:56.866655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893477 | REC_0000147 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 17.1 | 66 | female | 0 | 22 | 7.1 | 2 | alectinib 600 mg BID | 18.8 | false | MSS | 2026-03-15T05:35:56.866926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644483 | REC_0000148 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 15.5 | 69 | female | 1 | 13 | 2 | 4 | osimertinib 80 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:56.867222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253934 | REC_0000149 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 9.5 | 77 | female | 0 | 54 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:35:56.867490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596876 | REC_0000150 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8 | 60 | female | 0 | 22 | 3.7 | 7 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:56.867752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356381 | REC_0000151 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.8 | 75 | female | 1 | 41 | 4.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.7 | false | MSS | 2026-03-15T05:35:56.868002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838093 | REC_0000152 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 3.4 | 68 | female | 0 | 19 | 3.2 | 5 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:35:56.868315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926957 | REC_0000153 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.5 | 66 | female | 0 | 55 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:35:56.868593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807988 | REC_0000154 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 15.5 | 75 | female | 2 | 12 | 8.4 | 5 | entrectinib 600 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:56.868884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893380 | REC_0000155 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.7 | 59 | male | 0 | 14 | 7.7 | 5 | sotorasib 960 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:56.869174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686770 | REC_0000156 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8 | 58 | male | 0 | 58 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 6 | false | MSS | 2026-03-15T05:35:56.869469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560069 | REC_0000157 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.3 | 74 | female | 1 | 11 | 5.4 | 4 | alectinib 600 mg BID | 6.1 | false | MSI-H | 2026-03-15T05:35:56.869933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465315 | REC_0000158 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.8 | 73 | female | 2 | 26 | 4.3 | 4 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:56.870271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611507 | REC_0000159 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 22 | 5.6 | 76 | female | 0 | 70 | 2 | 0 | pembrolizumab 200 mg q3w | 50.6 | true | MSS | 2026-03-15T05:35:56.870558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311925 | REC_0000160 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.8 | 72 | female | 2 | 19 | 6.6 | 7 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:56.870845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464643 | REC_0000161 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 8.1 | 55 | female | 1 | 10 | 5.2 | 7 | entrectinib 600 mg daily | 7.3 | true | MSS | 2026-03-15T05:35:56.871093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301485 | REC_0000162 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 5.7 | 77 | female | 1 | 5 | 3.7 | 2 | pembrolizumab 200 mg q3w | 16.7 | true | MSS | 2026-03-15T05:35:56.871324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814314 | REC_0000163 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.6 | 83 | female | 2 | 0 | 5.3 | 7 | osimertinib 80 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:56.871561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370502 | REC_0000164 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 14.3 | 78 | male | 2 | 20 | 4.8 | 2 | osimertinib 80 mg daily | 15.6 | false | MSS | 2026-03-15T05:35:56.871799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684341 | REC_0000165 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 14.7 | 68 | female | 0 | 23 | 6.2 | 3 | entrectinib 600 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:56.872033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393968 | REC_0000166 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 32 | 3.1 | 66 | female | 1 | 44 | 4.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 52.1 | false | MSS | 2026-03-15T05:35:56.872333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606734 | REC_0000167 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 7.1 | 66 | female | 1 | 8 | 3.8 | 1 | osimertinib 80 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:56.872582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740536 | REC_0000168 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12 | 61 | male | 0 | 21 | 5.9 | 6 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:56.872819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448290 | REC_0000169 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 9.7 | 62 | female | 0 | 17 | 5.2 | 3 | entrectinib 600 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:56.873049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920869 | REC_0000170 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 4.8 | 69 | female | 0 | 19 | 3.9 | 5 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:35:56.873367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303027 | REC_0000171 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.5 | 75 | female | 1 | 21 | 6.9 | 4 | pembrolizumab 200 mg q3w | 7.5 | true | MSS | 2026-03-15T05:35:56.873608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907514 | REC_0000172 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.1 | 82 | female | 3 | 8 | 5.5 | 6 | sotorasib 960 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:56.873843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738414 | REC_0000173 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.1 | 63 | female | 1 | 12 | 4.7 | 7 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:56.874077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197190 | REC_0000174 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.9 | 57 | male | 0 | 25 | 7.3 | 7 | sotorasib 960 mg daily | 6.3 | false | MSS | 2026-03-15T05:35:56.874311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583269 | REC_0000175 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 17.3 | 68 | female | 1 | 23 | 5.7 | 0 | alectinib 600 mg BID | 23.5 | false | MSI-H | 2026-03-15T05:35:56.874544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610479 | REC_0000176 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.6 | 84 | female | 2 | 19 | 6.4 | 8 | alectinib 600 mg BID | 5.7 | true | MSS | 2026-03-15T05:35:56.874775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401383 | REC_0000177 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.8 | 68 | female | 0 | 16 | 2.9 | 7 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:56.875004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925053 | REC_0000178 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.7 | 72 | female | 2 | 14 | 6 | 4 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:56.875235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664640 | REC_0000179 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 5.2 | 63 | male | 0 | 18 | 6.7 | 2 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:56.875467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998257 | REC_0000180 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 6.5 | 55 | male | 0 | 15 | 4.3 | 8 | osimertinib 80 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:56.875698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189778 | REC_0000181 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.6 | 72 | female | 1 | 28 | 2.6 | 4 | sotorasib 960 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:56.875929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322334 | REC_0000182 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10 | 66 | female | 0 | 22 | 4.6 | 6 | alectinib 600 mg BID | 7.2 | true | MSI-H | 2026-03-15T05:35:56.876246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864025 | REC_0000183 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 10.1 | 69 | female | 0 | 20 | 5.3 | 6 | alectinib 600 mg BID | 9.5 | true | MSI-H | 2026-03-15T05:35:56.876543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345923 | REC_0000184 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 8.4 | 66 | female | 1 | 19 | 3.3 | 2 | entrectinib 600 mg daily | 5.5 | false | MSS | 2026-03-15T05:35:56.876781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201113 | REC_0000185 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.5 | 76 | female | 2 | 34 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:56.877012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840781 | REC_0000186 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.4 | 75 | male | 2 | 10 | 5.2 | 6 | osimertinib 80 mg daily | 7.2 | true | MSS | 2026-03-15T05:35:56.877251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328494 | REC_0000187 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 6.6 | 69 | female | 0 | 18 | 5 | 5 | entrectinib 600 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:56.877482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188645 | REC_0000188 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 8.4 | 77 | male | 3 | 56 | 4.8 | 7 | pembrolizumab 200 mg q3w | 7.5 | true | MSS | 2026-03-15T05:35:56.877714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222349 | REC_0000189 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.3 | 65 | female | 0 | 17 | 6.3 | 7 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:56.877946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228252 | REC_0000190 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 13 | 71 | female | 2 | 16 | 5.8 | 5 | sotorasib 960 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:56.878177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962275 | REC_0000191 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 5.9 | 66 | female | 0 | 20 | 6.6 | 2 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:56.878415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442070 | REC_0000192 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 15.7 | 81 | male | 3 | 11 | 4 | 6 | osimertinib 80 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:56.878654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895088 | REC_0000193 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 11.4 | 69 | female | 1 | 12 | 4.3 | 6 | entrectinib 600 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:56.878897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851463 | REC_0000194 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 11 | 79 | female | 3 | 20 | 4 | 1 | pembrolizumab 200 mg q3w | 14.4 | false | MSS | 2026-03-15T05:35:56.879144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290905 | REC_0000195 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.8 | 55 | male | 0 | 15 | 4.4 | 6 | entrectinib 600 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:56.879395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452302 | REC_0000196 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 11.1 | 73 | female | 1 | 5 | 4.6 | 4 | entrectinib 600 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:56.879737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485106 | REC_0000197 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 6.6 | 67 | female | 1 | 12 | 7 | 5 | pembrolizumab 200 mg q3w | 11.6 | false | MSS | 2026-03-15T05:35:56.879980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898759 | REC_0000198 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.8 | 49 | female | 0 | 18 | 6 | 8 | alectinib 600 mg BID | 9.4 | true | MSS | 2026-03-15T05:35:56.880289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992449 | REC_0000199 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 12.6 | 63 | female | 0 | 10 | 6.2 | 1 | osimertinib 80 mg daily | 23.7 | true | MSI-H | 2026-03-15T05:35:56.880536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904985 | REC_0000200 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 7.4 | 63 | male | 0 | 12 | 6.5 | 8 | sotorasib 960 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:56.880788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.